Currently out of the existing stock ratings of Etzer Darout, 114 are a BUY (73.55%), 39 are a HOLD (25.16%), 2 are a SELL (1.29%).

Etzer Darout

Work Performance Price Targets & Ratings Chart

Analyst Etzer Darout, currently employed at BMO, carries an average stock price target met ratio of 57.17% that have a potential upside of 43.8% achieved within 134 days.

Etzer Darout’s has documented 318 price targets and ratings displayed on 31 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TERN, Terns Pharmaceuticals at 25-Nov-2025.

Wall Street Analyst Etzer Darout

Analyst best performing recommendations are on FPRX (FIVE PRIME THERAPEUTICS).
The best stock recommendation documented was for TERN (TERNS PHARMACEUTICALS) at 11/4/2025. The price target of $27 was fulfilled within 14 days with a profit of $12.97 (92.44%) receiving and performance score of 66.03.

Average potential price target upside

of $33.64 (66.46%) on MYOK (MYOKARDIA).
of $31.46 (22.45%) on SGEN (SEAGEN).
of $30.79 (89.52%) on MRUS (MERUS BV).

DMAC DiaMedica Therapeutics MGNX MacroGenics MIRM Mirum Pharmaceuticals VERV Verve Therapeutics CTMX CytomX Therapeutics EXEL Exelixis FATE Fate Therapeutics GMAB Genmab AS IMGN ImmunoGen MRUS Merus BV SGEN Seagen NUVL Nuvalent XNCR Xencor FPRX Five Prime Therapeutics ALNY Alnylam Pharmaceuticals YMAB Y mAbs Therapeutics ARVN Arvinas FTSV Forty Seven AZN AstraZeneca PLC ADR CCCC C4 Therapeutics IVA Inventiva Sa BNTX BioNTech SE IGMS IGM Biosciences NVS Novartis AG ADR SRRK Scholar Rock Holding Corp TERN Terns Pharmaceuticals ACRV Acrivon Therapeutics, Common Stock QTTB Q32 Bio MYOK MyoKardia KYMR Kymera Therapeutics PTGX Protagonist Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Matthew Caufield (HC WAINWRIGHT)